Natalizumab discontinuation in a Dutch real-world cohort

E. M. E. Coerver; M. H. J. Wessels; Z. Y. G. van Lierop; Z. L. E. van Kempen; J. Killestein; E. M. M. Strijbis

doi:https://doi.org/10.1016/j.msard.2021.102974

Natalizumab discontinuation in a Dutch real-world cohort

E. M. E. Coerver, M. H. J. Wessels, Z. Y. G. van Lierop, Z. L. E. van Kempen, J. Killestein, E. M. M. Strijbis

Research output: Contribution to journal › Comment/Letter to the editor › Academic

3 Citations (Scopus)

Abstract

Objective: To determine characteristics of multiple sclerosis patients that discontinued natalizumab treatment in a real-world cohort. Methods: Data was collected from an ongoing observational cohort study of all natalizumab treated patients at the Amsterdam UMC. Results: Of 253 patients who ever received natalizumab treatment, 147 have discontinued treatment. The most frequent reason for treatment discontinuation was JC-virus (JCV) positivity. Conclusions: JCV positivity seems the most frequent reason for natalizumab discontinuation. The heterogeneity in treatment switches reflects the advances made in treatment options, and underlines the need for adequate patient counselling.

Original language	English
Article number	102974
Pages (from-to)	102974
Journal	Multiple Sclerosis and Related Disorders
Volume	52
DOIs	https://doi.org/10.1016/j.msard.2021.102974
Publication status	Published - 1 Jul 2021

Keywords

Antibodies, Viral
Cohort Studies
Humans
JC Virus
Leukoencephalopathy, Progressive Multifocal
Multiple sclerosis
Natalizumab
Treatment discontinuation

Access to Document

https://doi.org/10.1016/j.msard.2021.102974

Cite this

@article{bb52bc2d116d42f4b8a66f2ce0d64767,

title = "Natalizumab discontinuation in a Dutch real-world cohort",

abstract = "Objective: To determine characteristics of multiple sclerosis patients that discontinued natalizumab treatment in a real-world cohort. Methods: Data was collected from an ongoing observational cohort study of all natalizumab treated patients at the Amsterdam UMC. Results: Of 253 patients who ever received natalizumab treatment, 147 have discontinued treatment. The most frequent reason for treatment discontinuation was JC-virus (JCV) positivity. Conclusions: JCV positivity seems the most frequent reason for natalizumab discontinuation. The heterogeneity in treatment switches reflects the advances made in treatment options, and underlines the need for adequate patient counselling.",

keywords = "Antibodies, Viral, Cohort Studies, Humans, JC Virus, Leukoencephalopathy, Progressive Multifocal, Multiple sclerosis, Natalizumab, Treatment discontinuation",

author = "Coerver, {E. M. E.} and Wessels, {M. H. J.} and {van Lierop}, {Z. Y. G.} and {van Kempen}, {Z. L. E.} and J. Killestein and Strijbis, {E. M. M.}",

note = "Funding Information: E.M.E. Coerver and E.M.M. Strijbis received funding from ZonMW , grant number 848043001 , and Stichting MS Research , grant number 17 - 992 . Publisher Copyright: {\textcopyright} 2021 Elsevier B.V.",

year = "2021",

month = jul,

day = "1",

doi = "https://doi.org/10.1016/j.msard.2021.102974",

language = "English",

volume = "52",

pages = "102974",

journal = "Multiple Sclerosis and Related Disorders",

issn = "2211-0348",

publisher = "Elsevier",

}

TY - JOUR

T1 - Natalizumab discontinuation in a Dutch real-world cohort

AU - Coerver, E. M. E.

AU - Wessels, M. H. J.

AU - van Lierop, Z. Y. G.

AU - van Kempen, Z. L. E.

AU - Killestein, J.

AU - Strijbis, E. M. M.

N1 - Funding Information: E.M.E. Coerver and E.M.M. Strijbis received funding from ZonMW , grant number 848043001 , and Stichting MS Research , grant number 17 - 992 . Publisher Copyright: © 2021 Elsevier B.V.

PY - 2021/7/1

Y1 - 2021/7/1

N2 - Objective: To determine characteristics of multiple sclerosis patients that discontinued natalizumab treatment in a real-world cohort. Methods: Data was collected from an ongoing observational cohort study of all natalizumab treated patients at the Amsterdam UMC. Results: Of 253 patients who ever received natalizumab treatment, 147 have discontinued treatment. The most frequent reason for treatment discontinuation was JC-virus (JCV) positivity. Conclusions: JCV positivity seems the most frequent reason for natalizumab discontinuation. The heterogeneity in treatment switches reflects the advances made in treatment options, and underlines the need for adequate patient counselling.

AB - Objective: To determine characteristics of multiple sclerosis patients that discontinued natalizumab treatment in a real-world cohort. Methods: Data was collected from an ongoing observational cohort study of all natalizumab treated patients at the Amsterdam UMC. Results: Of 253 patients who ever received natalizumab treatment, 147 have discontinued treatment. The most frequent reason for treatment discontinuation was JC-virus (JCV) positivity. Conclusions: JCV positivity seems the most frequent reason for natalizumab discontinuation. The heterogeneity in treatment switches reflects the advances made in treatment options, and underlines the need for adequate patient counselling.

KW - Antibodies, Viral

KW - Cohort Studies

KW - Humans

KW - JC Virus

KW - Leukoencephalopathy, Progressive Multifocal

KW - Multiple sclerosis

KW - Natalizumab

KW - Treatment discontinuation

UR - http://www.scopus.com/inward/record.url?scp=85105715255&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.msard.2021.102974

DO - https://doi.org/10.1016/j.msard.2021.102974

M3 - Comment/Letter to the editor

C2 - 33990055

SN - 2211-0348

VL - 52

SP - 102974

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

M1 - 102974

ER -

Natalizumab discontinuation in a Dutch real-world cohort

Abstract

Keywords

Access to Document

Other files and links

Cite this